

DR. ANDREA RAVIDÀ (Orcid ID : 0000-0002-3029-8130)

DR. CARLOS GARAICOA-PAZMINO (Orcid ID : 0000-0001-8486-6810)

DR. ALBERTO MONJE (Orcid ID : 0000-0001-8292-1927)

PROF. HOM-LAY WANG (Orcid ID : 0000-0003-4238-1799)

Article type : Original Article Implant Dentistry

### **Influence of keratinized mucosa on the surgical therapeutical outcomes of peri-implantitis**

Andrea Ravidà<sup>1</sup> DDS, MS, Islam Saleh<sup>1</sup> BDS, Rafael Siqueira<sup>1</sup> DDS, MS, PhD, Carlos Garaicoa Pazmino<sup>2</sup> DDS, MS, Muhammad H. A. Saleh<sup>1,3</sup> BDS, MS, Alberto Monje<sup>4</sup> DDS, MS, PhD, Hom-Lay Wang<sup>1</sup> DDS, MS, PhD

<sup>1</sup>Graduate Periodontics, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA.

<sup>2</sup> Department of Periodontology, School of Dentistry, Oregon Health & Science University, Portland, OR.

<sup>3</sup>Department of Periodontics, University of Louisville School of Dentistry, Louisville, KY, USA.

<sup>4</sup>Department Periodontology, Universitat Internacional de Catalunya, Barcelona, Spain

#### **Corresponding author:**

Hom-Lay Wang, DDS, MS, PhD

Department of Periodontics and Oral Medicine

University of Michigan School of Dentistry

1011 North University Avenue

Ann Arbor, Michigan 48109-1078, USA.

TEL: +1 (734) 763-3383

**This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/JCPE.13250](https://doi.org/10.1111/JCPE.13250)**

This article is protected by copyright. All rights reserved

E-mail address: homlay@umich.edu

**Word count:** 3819 words

**Tables and figures:** 5 tables, 2 figures, 2 supplementary table, 1 supplementary figure

**Key words:** Dental implants, peri-implantitis, disease management, keratinized mucosa

**Conflict of interest and source of funding:** The authors do not have any financial interests, either directly or indirectly, in the products or information listed in the paper. This paper was partially supported by the University of Michigan Periodontal Graduate Student Research Fund.

#### **Abstract**

**Aim:** To assess the impact of keratinized mucosa (KM) width around dental implants on surgical therapeutic outcomes when treating peri-implantitis.

**Material and Methods:** Surgically treated peri-implantitis implants were divided into two groups (KM width <2 mm and  $\geq 2$  mm). Retrospective data was obtained after implant placement (T0) and the day of peri-implantitis surgical treatment (T1). Patients were later recruited ( $\geq 1$  year after T1) for clinical and radiographic examination (T2). Outcomes were analyzed using generalized estimating equation (GEE) models.

**Results:** 40 patients (68 implants) (average follow-up:  $52.4 \pm 30.5$  months) were included in this study. From T0-T1, no differences were found between KM groups in terms of peri-implant probing depths (PPD) and bleeding on probing (BOP). However, sites with <2 mm KM exhibited significantly higher suppuration (SUP) and lower marginal bone level (MBL) ( $p > 0.01$ ). Between T1-T2, no major differences were noted on PPD reduction, BOP and MBL changes between the two groups. GEE modelling demonstrated that MBL severity prior to surgical therapy was a better predictor for implant survival than KM width.

**Conclusion:** Surgical outcome in treating peri-implantitis was influenced by the severity of bone loss present at the time of treatment and not by the presence of keratinized mucosa at the time of treatment.

**Clinical relevance:**

*Scientific rationale for the study:* The significance of keratinized mucosa on peri-implant diseases has been extensively investigated. Nevertheless, the impact of keratinized mucosa on therapeutic outcomes remains unknown.

*Principal findings:* Keratinized mucosa might play a more crucial role in the progression of peri-implant diseases rather than in the response to surgical therapy.

*Practical implication:* While progression of peri-implantitis is associated with a lack of keratinized mucosa, therapeutic outcomes are mainly influenced by severity of bone loss.

Author Manuscript

## Introduction

It is beyond dispute that dental implants have long-term ( $\geq 10$  year) survival rates over 90% (Pjetursson et al., 2012, Howe et al., 2019). However, dental implants are subject to biological complications known as peri-implant diseases (Renvert et al., 2018a). While tissue inflammation is a hallmark of both peri-implant mucositis and peri-implantitis, only the latter form presents with progressive loss of supporting bone (Lindhe et al., 2008). The reported prevalence of peri-implant mucositis ranged from 19-65% (weighted mean of 42.9%), while for peri-implantitis prevalence ranged from 1-47% (weighted mean of 22%) (Derks and Tomasi, 2015). Peri-implantitis prevalence was positively correlated with function time and negatively correlated with threshold for bone loss (Derks and Tomasi, 2015).

Several conditions have been identified as putative risk factors or risk indicators for peri-implantitis including diabetes, smoking, history of periodontitis, poor plaque control, lack of regular maintenance therapy, inadequate width of keratinized mucosa (KM), implant malpositioning, among others (Schwarz et al., 2018c, Hammerle and Tarnow, 2018). One factor that is routinely investigated is the significance of KM on peri-implant health (Chung et al., 2006, Kim et al., 2009, Lin et al., 2013). A lack of KM has been associated with higher levels of prostaglandin E2 (Zigdon and Machtei, 2008), which might explain the positive effect of KM on the development and resolution of experimental mucositis in humans (Schwarz et al., 2018b). Hence, its presence seems essential for maintenance of long-term peri-implant health (Listgarten et al., 1991). While few studies reported that presence of KM was associated with peri-implantitis (Roos-Jansaker et al., 2006), there is building evidence to support a positive correlation between the presence of peri-implantitis and sites with  $< 2$ mm KM (Bouri et al., 2008), where others suggest that the evidence to support this finding is limited (Wennstrom et al., 1994, Bengazi et al., 1996, Wennstrom and Derks, 2012, Frisch et al., 2015, Crespi et al., 2010). Recent data supports the understanding that an adequate width of KM is crucial in patients exhibiting poor compliance with peri-implant maintenance (Monje and Blasi, 2019), but plays a lesser role in fully compliant patients (Lim et al., 2019).

Although disagreement exists in the literature, the majority of studies agreed that the absence or lack ( $< 2$ mm) of KM was more likely to be associated with increased plaque accumulation, tissue inflammation, recession, attachment loss and reduced quality of self-performed oral hygiene measures (Lin et al., 2013, Gobbato et al., 2013, Ueno et al., 2016). These findings suggest that the presence of KM should be important not only for maintaining peri-implant health, but also during surgical therapy of peri-implantitis and long-term maintenance.

The influence of KM on the prevalence of peri-implant diseases can be argued according to population studies. However, it remains unknown whether the presence of KM

plays a significant role in the treatment of peri-implant diseases. Hence, the aim of this study was to explore the impact of KM on the outcomes of peri-implantitis treatment before and after surgical therapy.

## **Material and methods**

This retrospective study was conducted in accordance with the Declaration of Helsinki on human studies, approved by the University of Michigan School of Dentistry Institutional Review Board (IRB) for Human Studies (HUM00148346), and registered in Clinicaltrials.gov (ID: NCT03772652). Physical and digital records collected from patients treated for peri-implantitis from 2008-2018 at the University of Michigan School of Dentistry were screened and evaluated by three examiners (IS, AR, RS). Patients with functional treated implants were invited to participate in the study and recruited after signing a written informed consent form for data collection from January 2019 to June 2019. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed during the preparation of the manuscript.

### *Eligibility criteria*

To be included in this study, patients had to fall under the following predetermined eligibility criteria: 1) presence of at least one dental implant previously diagnosed with peri-implantitis using the American Academy of Periodontology (AAP)/European Federation of Periodontology (EPF) 2017 World Workshop on the Classification of Periodontal and Peri-implant Diseases and Conditions guidelines (Berglundh et al., 2018a), 2) complete clinical and radiographic pre-surgical documentation, 3) documented follow-up of  $\geq 1$ -year following surgical therapy for peri-implantitis with either resective or regeneration therapy (Supplementary Table 1), 4)  $\geq 1$  maintenance session per year within the University of Michigan School of Dentistry after surgical treatment of peri-implantitis and 5) presence of opposing occlusion. Patients were excluded if: 1) clinical and radiographic records were incomplete or not available, 2) follow-up  $< 1$ -year after surgical therapy, and 3) peri-implantitis treatment and maintenance therapy was rendered outside the University of Michigan School of Dentistry.

### *Data collection and classification*

As part of the data collection process, all relevant patient information including gender, age at the time of the treatment of peri-implantitis, self-reported cigarette consumption ( $\geq 1$  cigarette/day), diabetes, and history of periodontal disease as defined by the World Workshop (Tonetti et al., 2018) were collected. Patients were assessed at T0, T1, and T2, where T0 represented implant placement or prosthetic placement, T1 represented peri-implantitis

treatment, and T2 represented follow-up after treatment where patients were recalled. Patients files were examined at T0 to collect clinical parameters such as KM width and radiographs. KM width was defined as the distance measured between the free mucosal margin to the mucogingival junction at the mid-buccal site, utilizing the North Carolina probe (Hu-Friedy, Chicago, IL, USA). The selected cases were then separated into two groups based on the amount of KM:  $KM < 2\text{mm}$  and  $KM \geq 2\text{mm}$ . The following information was collected from patient files at T1: KM width, radiographs, peri-implant probing depths (PPD) (recorded in millimeters using a North Carolina probe), bleeding on probing (BOP) and suppuration (SUP) (dichotomous (1/0) scale using a North Carolina probe), and peri-implant marginal bone level (MBL). Peri-implant MBL was considered as the distance between the most coronal part of the implant expected to be in bone-to-implant contact (for tissue level implants: the interface between the polished collar and rough surface, and for bone level implants with rough surface: the platform level) to the most coronal point of the implant body in contact with bone. For each radiograph, the MBL was measured by two authors (CGP, RS) at the mesial and distal aspects of the affected implants using commercially available software (ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA). MBL was also categorized in percentage (<25%; 25% - 50%; or >50%) of the implant at the interproximal sites that had no bone-implant-contact considering the length of the implant. Implant design was taken in consideration for this analysis and therefore implants with a polished collar were analyzed as complete length being from the smooth-rough interface in apical direction. Repeated measurements of 15 implants were conducted to quantify mean intra- and inter-agreement measurement errors:  $0.36 \pm 0.4$  and  $0.57 \pm 0.6$ , respectively. Changes in the width of KM from T0 to T1 was observed. Implants that were initially in the  $KM \geq 2\text{mm}$  group at T0 might have switched to the  $KM < 2\text{mm}$  group by this point (T1) or vice versa; depending on the rendered KM lose or gain.

If the treated implant was found to be in function based on the information on file in the patient chart during the last appointment in our clinic, the patient was contacted and invited to participate in this study (T2 appointment). In case of implant failure, the date of the implant removal was recorded, and the implant was included in the analysis, but the patient was not contacted (no T2 appointment). During patient recalls, all the aforementioned clinical and radiographic parameters were remeasured. In addition, plaque index (Silness and Loe, 1964) was recorded by one expert examiner (CGP). Additional information regarding type of surgical intervention (resective surgery or guided bone regeneration), previous non-surgical therapy, number of maintenance visits, systemic antibiotic prescription, and the characteristics of the implants and prosthesis were also gathered.

### *Treatment success*

An extensive search of all available peri-implantitis treatment success criteria was performed. The most employed success criteria after treatment of peri-implantitis were defined as PPD <5mm, absence of BOP/SUP, and no progressive radiographic marginal bone loss (Criteria 1) (Charalampakis et al., 2011, Heitz-Mayfield and Mombelli, 2014, Berglundh et al., 2018b, Isler et al., 2018, Heitz-Mayfield et al., 2018, Cha et al., 2019, de Tapia et al., 2019). Criteria 1 was used to define success after both resective and regenerative treatment at T2. An additional composite modified criteria (Criteria 2) was used at T2 to define success around implant sites treated with regenerative therapy (PPD <5mm, modified sulcus bleeding index [SBI] in <25% of sites, and defect bone fill of >25% or >1mm) (Renvert et al., 2018b, Roos-Jansaker et al., 2014, Mombelli et al., 1987).

### *Statistical analysis*

Binary logistic regression was conducted to evaluate post-surgical outcomes based on pre-surgical KM width using generalized estimating equations (GEE) adjusted to account for differences in follow-up period, number of maintenance visits, and type of procedure performed between T0, T1 and T2. The changes in BOP and SUP rates from T1 to T2 amongst the two KM groups were analyzed with a model labeled as "interaction group KM-time". For changes in mean PPD (at six sites) and mean MBL (mesial and distal), general linear models were used under the GEE approach. The GEE methodology was used to control the intra-subject correlation due to the multiplicity of implants. The level of significance utilized in the analyses was 5% ( $\alpha = 0.05$ ). A logistic regression model reached a power of 82.6% to detect an odds ratio (OR) = 4 and deemed significant in a hypothetical sample of 68 totally independent implants assuming a confidence level of 95%. Due to the multi-level design of the data (several implants per patient), the power was corrected assuming a moderate intra-subject correlation ( $\rho = 0.5$ ) resulting in a power of 72%.

### **Results**

One-hundred forty three patients received treatment of peri-implantitis at University of Michigan school of Dentistry, however 103 were excluded for the following reason: 23 patients had the implants placed outside the school and information at T0 were not available, 2 patients passed away, 6 patients moved and were not able to come to the appointment at T2, 14 Patients could not be contacted, 33 patients had incomplete information at T0 or T1, 14 did not want to be part of the research study, 5 patients were treated before implants were restored

and for 6 patients the implants were extracted < 1 year after surgical treatment of peri-implantitis. A total of 40 patients including 22 women (55%) and 18 men (45%) with a mean age of  $64.5 \pm 9.0$  years (range: 43-87 years) were recruited for this study. At T0, a total of 68 implants (KM < 2mm = 26; KM  $\geq$  2 = 42) was included in the study (Supplementary Table 2). Thirteen implants with KM  $\geq$  2mm at T0 (implant placement) lost KM width due to the peri-implant disease process and were then moved to the KM < 2mm group at T1 (peri-implantitis surgical treatment). Hence, 39 implants with <2mm KM and 29 with  $\geq$ 2mm KM were diagnosed with and treated for peri-implantitis (T1) receiving either resective or regenerative therapy with a mean follow-up of  $52.4 \pm 30.5$  months (Supplementary figure 1). In total, 10% percent of the patients were smokers, 10% presented with hyperglycaemia, and 62.5% had a history of periodontitis at the time of the surgical phase for the management of peri-implantitis. Demographic data and relevant pre-/post-surgical information were included in Table 1.

#### *Changes from implant placement to the day of surgery (T0-T1)*

The duration of time between implant placement and surgical treatment of peri-implantitis was longer for dental implants with <2mm KM relative to those with  $\geq$ 2mm KM (T0-T1) ( $p = 0.087$ ). Furthermore, patients with peri-implant sites presenting with <2mm KM exhibited a similar frequency of periodontal maintenance sessions ( $p = 0.607$ ). The association between KM, clinical, and radiographic parameters at T1 are shown in Table 2. At T1 no statistically significant difference was found between the two groups of KM width in terms of PPD and BOP ( $p > 0.05$ ). However, sites with <2mm KM had a 5-fold increase (OR = 5.02) in SUP compared to sites with  $\geq$ 2mm KM ( $p = 0.025$ ). Simple linear regression using GEE to control differences in time and maintenance showed that sites with <2mm KM exhibited significantly lower MBL at T1 than sites with  $\geq$ 2mm KM ( $p < 0.01$ ). Sites with <2mm KM had a 5-fold higher risk for having MBL >25% ( $p = 0.012$ ) and 11-fold higher risk for MBL >50% ( $p = 0.011$ ) compared to sites with  $\geq$ 2mm KM.

#### *Changes after treatment of peri-implantitis (T1-T2)*

Clinical and radiographical parameters prior surgical treatment for peri-implantitis are shown in Table 3. After treatment, 12 out of 68 implants were removed after surgical treatment giving an overall survival rate of 82.4%. When considering KM width, 11 out of 39 implants (28.2%) were removed in the <2mm KM group, while only 1 out of 29 implants (3.4%) were lost in the  $\geq$ 2mm KM group. Treated implant sites with <2mm KM displayed a shorter follow-up after treatment ( $p = 0.075$ ) when compared to  $\geq$ 2mm KM sites.

After adjusting the model for the number of maintenance visits and MBL at T1, it was found that sites with <2mm KM had 6-fold increased risk for failure relative to sites with  $\geq$ 2mm KM



( $p=0.13$ ). It should be noted that multivariate analysis yielded that the position of the MBL could predict implant survival rate prior to treatment being rendered ( $p=0.05$ ) (Table 4). 7 of the 11 implant failures in the  $<2\text{mm}$  KM group presented with MBL  $>50\%$  at T1. The risk of future implant failure increased by 65% for each additional millimeter of MBL measured at T1.

In terms of PPD reduction, no statistically significant difference was found after adjusting for differences in follow-up time and number of maintenance visits between the two KM width groups regardless of regenerative ( $p=0.1$ ) or resective therapy ( $p=0.5$ ) (Figure 2A). At T1, BOP was present at 100% of peri-implant sites in both groups. At T2, BOP was measured at 90% of sites in both groups after regenerative therapy, and at 88.9% (KM  $< 2\text{mm}$ ) and 87.5% (KM  $\geq 2\text{mm}$ ) after resective therapy ( $p>0.05$ ). SUP was reduced from 80% to 40% at sites with  $<2\text{mm}$  KM and from 60% to 45% at sites with  $\geq 2\text{mm}$  when treated with regenerative therapy ( $p>0.05$ ). SUP decreased from 72.2% to 5.6% in the  $<2\text{mm}$  KM group and from 57% to 42.9% at sites with  $\geq 2\text{mm}$  KM after resective therapy ( $p<0.01$ ). MBL changes in both KM groups showed no differences ( $p>0.05$ ) between resective or regenerative treatment approaches (Figure 2B).

During T2, PI scores were  $1.37 \pm 0.88$  at the sites with  $< 2\text{mm}$  KM and  $1.36 \pm 0.81$  at sites with  $\geq 2\text{mm}$  KM ( $p>0.05$ ). GI score was significantly ( $p=0.013$ ) lower at sites with  $<2\text{mm}$  KM ( $1.56 \pm 0.64$ ) when compared to the  $\geq 2\text{mm}$  KM group ( $1.92 \pm 0.57$ ). Maintenance frequency exhibited a significant effect on GI score (beta = -0.33,  $p = 0.001$ ); for each additional annual maintenance visit, the GI score was reduced by 0.20 points.

#### *Success rate after treatment of peri-implantitis*

Table 5 shows the number and percentage of implants that responded to surgical therapy. Based on the selected criteria, the overall treatment success was accomplished in 10.3% and 7.7% of cases among sites with  $\geq 2\text{mm}$  and  $<2\text{mm}$  KM, respectively. Success rates were 9.1% and 23.5% when regeneration therapy was performed at sites with  $\geq 2\text{mm}$  and  $<2\text{mm}$  KM, respectively. Overall, no significant influence of the KM width on the criteria was found between the groups ( $p>0.05$ ).

## **Discussion**

### *Principal findings*

The significance of KM width on frequency of peri-implant diseases is a heavily debated subject in the literature. Current evidence underlines the importance of frequent periodontal and peri-implant maintenance, suggesting that in highly compliant patients, KM plays a null role in the prevention of biological complications (Lim et al., 2019). Conversely, in poorly compliant patients, the presence of  $\geq 2\text{mm}$  of KM has been demonstrated to be beneficial for long-term

outcomes (Romanos et al., 2015, Monje and Blasi, 2019). Generally, the influence of peri-implant KM on peri-implantitis therapeutic outcomes is poorly understood.

Findings from this retrospective analysis suggest that peri-implant sites with minimal KM display more severe forms of peri-implantitis. Nevertheless, our results failed to exhibit an association between the width of the initial band of KM and the therapeutic outcome of peri-implantitis. Our findings revealed that lower marginal bone level around implants prior to surgical treatment contributes towards therapeutical success and implant survival to a greater extent than KM width. However, the presence of  $\geq 2$ mm of KM around implant sites diagnosed with peri-implantitis led to higher survival rates compared to sites lacking KM. Regardless of the presence or absence of KM, severe forms of peri-implantitis are more prone to showing unsatisfactory outcomes after surgical therapy. Following treatment, BOP was yet measured at 90% of sites in both groups after either therapies. Noticeable variations between the incidence of BOP and clinically manifested peri-implantitis was previously reported (Mombelli et al., 2012). More recently, another group reported that following surgical peri-implantitis therapy, no BOP was demonstrated in only 14% of implants treated, and almost only 2% at patient level (Koldsland et al., 2018). Both findings in additions to the results of the current study agrees with the conclusions of a recent systematic review; that the extent to which BOP can identify peri-implantitis seems to be limited (Hashim et al., 2018). Noteworthy also that despite reconstructive treatment in one arm of the study, only one group experienced bone gain (Figure 2B). This might be partially explained by the wide-ranging standard deviation we had, were few implants had modest amounts of bone gain, others had significant bone loss. In contrast, a systematic review reported that 10.4% of the included implants from 6 clinical trials showed complete bone fill, 85.5% showed partial defect fill, and only 4% experienced bone loss (Sahrman et al., 2011).

#### *Agreements and disagreements with previous studies*

Peri-implantitis is characterized by a non-linear and accelerating pattern of peri-implant marginal bone loss (Derks et al., 2016), where a lack of KM has been suggested to contribute towards the onset of peri-implantitis (Gobbato et al., 2013, Lin et al., 2013). In fact, a very recent prospective follow-up study demonstrated that KM width and time in function had a statistically significant effect on MBL (Perussolo et al., 2018). This was supportive of previous findings (Zigdon and Machtei, 2008). Schwarz et al. showed that sites with  $\geq 2$  mm KM displayed less efficient resolution of experimental peri-implant mucositis (Schwarz et al., 2018a). Our findings underlined that the lack of keratinized mucosa contributes towards increased peri-implantitis severity.

This study is the first to investigate the impact of KM width on peri-implantitis therapeutic outcomes. Recent clinical trials concurred that non-surgical treatments are often insufficient in preventing further bone loss at peri-implantitis sites, and that only surgical approaches significantly diminish the progression of bone loss (Faggion et al., 2014, Karlsson et al., 2019). It is also safe to assume that surgical interventions are best reserved for moderate and advanced peri-implantitis cases (Aljateeli et al., 2012, Esposito et al., 2012). As for the modality of surgery, a systematic review that investigated different surgical modalities for treatment of peri-implantitis was unable to support a specific type of treatment modality (Heitz-Mayfield and Mombelli, 2014). Our findings further elucidated that advanced bone loss present at the time of peri-implantitis treatment has a major impact on determining therapeutic outcomes. Hence, the therapeutic prognosis of advanced forms of peri-implantitis in the vast majority of cases is unfavorable or hopeless, regardless of the presence or lack of KM. In this sense, 7 of the 11 failures in the <2mm KM group presented at T1 with MBL >50%. Our study demonstrated there was no difference in PI, PPD reduction, or MBL between both KM groups at T2. However, the effects of KM width on SUP need further clarification, since resective procedures decreased SUP from 72.2% to 5.6% in the <2mm KM group, but only decreased SUP from 57% to 42.9% in the  $\geq 2$  mm KM group ( $p < 0.01$ ). It is speculated that this marked reduction of SUP is merely due to the high implant failure rate seen in the <2mm KM group, where 9 implants with SUP failed, and thus were not included in the analysis. Based on our analysis, each additional millimeter of MBL increased the risk of implant failure by 65%. While such association has not been reported in previous clinical trials, it seems to be in agreement with the general consensus of the literature (Schwarz et al., 2010, Sinjab et al., 2018, Froum and Rosen, 2012)

All patients recruited for this study were compliant with peri-implant maintenance therapy having a minimum of one maintenance session per year after treatment of peri-implantitis. A recent study investigated the outcomes of surgically treated implants with peri-implantitis that were maintained regularly (Serino et al., 2015). Results showed that 39% of the treated implants had concomitant BOP/SUP upon probing after 6 months. Interestingly, in our study GI scores were significantly lower at sites with <2mm KM ( $1.56 \pm 0.64$ ) than sites with  $\geq 2$  mm KM ( $1.92 \pm 0.57$ ). It is noteworthy that our patients that fell within the <2mm KM group exhibited a relatively increased frequency of supportive peri-implant maintenance visits from T1 to T2. This is in agreement with previous findings (Lim et al., 2019).

Treatment success was set according to the most commonly used criteria proposed by Heitz-Mayfield and Mombelli (Heitz-Mayfield and Mombelli, 2014) and a specific criteria intended for regenerative approaches (Mombelli et al., 1987, Renvert et al., 2018b, Roos-

Jansaker et al., 2014). Our treatment success rates might seem to be significantly lower compared to other studies (Renvert et al., 2018b, Heitz-Mayfield et al., 2018), mainly due to a high rate of residual BOP at T2. BOP has been suggested to be a clinical sign of peri-implant mucositis and peri-implantitis. As inferred before, the magnitude to which BOP, as a single variant, indicates the presence of peri-implantitis remains unknown (Monje et al., 2018a). Marked variations between the incidence of BOP and clinically manifested peri-implantitis exist (Mombelli et al., 2012). In fact, assessments comparing teeth and implants in the same patients have shown that in the absence of disease, BOP was more frequent at implant sites (Cionca et al., 2016). These findings could result from disturbing blood vessels due to an increased depth of probe penetration into healthy peri-implant mucosa. Hence, careful interpretation of BOP values is necessary, since it might lead to a high false positive rate when identifying the presence of peri-implant disease. Assessment of bleeding tendency using the modified sulcus bleeding index, or mucosal inflammation using the implant mucosal index, is likely more accurate in the detection of true peri-implant breakdown (Mombelli et al., 1987, Monje et al., 2018b, French et al., 2016).

#### *Limitations and recommendations for future studies*

Our study is not free of limitations inherent to the retrospective design of the investigation. Although our study included only compliant patients, some could be considered erratic compliers (<2 visits/year). Erratic compliers have been reported to perform as poorly as non-compliant patients (Monje et al., 2017). Furthermore, the length, diameter, brand, and surface treatment of implants were not included in the multivariate analysis, since the number of implant variations used were too substantial to yield statistical significance for the patient sample studied. Due to the multi-level design of the statistical analysis, a power of 72% was reached.

It should be noticed that the implant literature has been scarce in terms of considering KM association with the outcome of surgical procedures of peri-implantitis. Efforts should therefore be undertaken to include such outcome measures in future clinical studies.

#### **Conclusion**

Peri-implant bone loss as a result of peri-implantitis is further aggravated in scenarios lacking keratinized mucosa. Nevertheless, surgical outcome in treating peri-implantitis was influenced by the severity of bone loss present at the time of treatment and not by the presence of keratinized mucosa at the time of treatment. Hence, the assessment of peri-implant bone loss prior to surgical therapy is a more accurate predictor of therapeutic outcomes when treating peri-implantitis.

**Acknowledgements:**

The authors would like to thank Dr. Matthew Galli (Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry) for his contribution on the preparation of the manuscript.

Author Manuscript

## REFERENCES

- Aljateeli, M., Fu, J. H. & Wang, H. L. (2012) Managing peri-implant bone loss: current understanding. *Clin Implant Dent Relat Res* **14 Suppl 1**, e109-118. doi:10.1111/j.1708-8208.2011.00387.x.
- Bengazi, F., Wennstrom, J. L. & Lekholm, U. (1996) Recession of the soft tissue margin at oral implants. A 2-year longitudinal prospective study. *Clin Oral Implants Res* **7**, 303-310.
- Berglundh, T., Armitage, G., Araujo, M. G., Avila-Ortiz, G., Blanco, J., Camargo, P. M., Chen, S., Cochran, D., Derks, J., Figuero, E., Hammerle, C. H. F., Heitz-Mayfield, L. J. A., Huynh-Ba, G., Iacono, V., Koo, K. T., Lambert, F., McCauley, L., Quirynen, M., Renvert, S., Salvi, G. E., Schwarz, F., Tarnow, D., Tomasi, C., Wang, H. L. & Zitzmann, N. (2018a) Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. *J Clin Periodontol* **45 Suppl 20**, S286-S291. doi:10.1111/jcpe.12957.
- Berglundh, T., Wennstrom, J. L. & Lindhe, J. (2018b) Long-term outcome of surgical treatment of peri-implantitis. A 2-11-year retrospective study. *Clin Oral Implants Res* **29**, 404-410. doi:10.1111/clr.13138.
- Bouri, A., Jr., Bissada, N., Al-Zahrani, M. S., Faddoul, F. & Nouneh, I. (2008) Width of keratinized gingiva and the health status of the supporting tissues around dental implants. *Int J Oral Maxillofac Implants* **23**, 323-326.
- Cha, J. K., Lee, J. S. & Kim, C. S. (2019) Surgical Therapy of Peri-Implantitis with Local Minocycline: A 6-Month Randomized Controlled Clinical Trial. *J Dent Res* **98**, 288-295. doi:10.1177/0022034518818479.
- Charalampakis, G., Rabe, P., Leonhardt, A. & Dahlen, G. (2011) A follow-up study of peri-implantitis cases after treatment. *J Clin Periodontol* **38**, 864-871. doi:10.1111/j.1600-051X.2011.01759.x.
- Chung, D. M., Oh, T. J., Shotwell, J. L., Misch, C. E. & Wang, H. L. (2006) Significance of keratinized mucosa in maintenance of dental implants with different surfaces. *J Periodontol* **77**, 1410-1420. doi:10.1902/jop.2006.050393.

- Cionca, N., Hashim, D., Cancela, J., Giannopoulou, C. & Mombelli, A. (2016) Pro-inflammatory cytokines at zirconia implants and teeth. A cross-sectional assessment. *Clin Oral Investig* **20**, 2285-2291. doi:10.1007/s00784-016-1729-z.
- Crespi, R., Cappare, P. & Gherlone, E. (2010) A 4-year evaluation of the peri-implant parameters of immediately loaded implants placed in fresh extraction sockets. *J Periodontol* **81**, 1629-1634. doi:10.1902/jop.2010.100115.
- de Tapia, B., Valles, C., Ribeiro-Amaral, T., Mor, C., Herrera, D., Sanz, M. & Nart, J. (2019) The adjunctive effect of a titanium brush in implant surface decontamination at peri-implantitis surgical regenerative interventions: A randomized controlled clinical trial. *J Clin Periodontol* **46**, 586-596. doi:10.1111/jcpe.13095.
- Derks, J., Schaller, D., Hakansson, J., Wennstrom, J. L., Tomasi, C. & Berglundh, T. (2016) Peri-implantitis - onset and pattern of progression. *J Clin Periodontol* **43**, 383-388. doi:10.1111/jcpe.12535.
- Derks, J. & Tomasi, C. (2015) Peri-implant health and disease. A systematic review of current epidemiology. *J Clin Periodontol* **42 Suppl 16**, S158-171. doi:10.1111/jcpe.12334.
- Esposito, M., Grusovin, M. G. & Worthington, H. V. (2012) Interventions for replacing missing teeth: treatment of peri-implantitis. *Cochrane Database Syst Rev* **1**, CD004970. doi:10.1002/14651858.CD004970.pub5.
- Faggion, C. M., Jr., Listl, S., Fruhauf, N., Chang, H. J. & Tu, Y. K. (2014) A systematic review and Bayesian network meta-analysis of randomized clinical trials on non-surgical treatments for peri-implantitis. *J Clin Periodontol* **41**, 1015-1025. doi:10.1111/jcpe.12292.
- French, D., Cochran, D. L. & Ofec, R. (2016) Retrospective Cohort Study of 4,591 Straumann Implants Placed in 2,060 Patients in Private Practice with up to 10-Year Follow-up: The Relationship Between Crestal Bone Level and Soft Tissue Condition. *Int J Oral Maxillofac Implants* **31**, e168-e178. doi:10.11607/jomi.4932.
- Frisch, E., Ziebolz, D., Vach, K. & Ratka-Kruger, P. (2015) The effect of keratinized mucosa width on peri-implant outcome under supportive postimplant therapy. *Clin Implant Dent Relat Res* **17 Suppl 1**, e236-244. doi:10.1111/cid.12187.

- Froum, S. J. & Rosen, P. S. (2012) A proposed classification for peri-implantitis. *Int J Periodontics Restorative Dent* **32**, 533-540.
- Gobbato, L., Avila-Ortiz, G., Sohrabi, K., Wang, C. W. & Karimbux, N. (2013) The effect of keratinized mucosa width on peri-implant health: a systematic review. *Int J Oral Maxillofac Implants* **28**, 1536-1545. doi:10.11607/jomi.3244.
- Hammerle, C. H. F. & Tarnow, D. (2018) The etiology of hard- and soft-tissue deficiencies at dental implants: A narrative review. *J Clin Periodontol* **45 Suppl 20**, S267-S277. doi:10.1111/jcpe.12955.
- Hashim, D., Cionca, N., Combescure, C. & Mombelli, A. (2018) The diagnosis of peri-implantitis: A systematic review on the predictive value of bleeding on probing. *Clin Oral Implants Res* **29 Suppl 16**, 276-293. doi:10.1111/clr.13127.
- Heitz-Mayfield, L. J. & Mombelli, A. (2014) The therapy of peri-implantitis: a systematic review. *Int J Oral Maxillofac Implants* **29 Suppl**, 325-345. doi:10.11607/jomi.2014suppl.g5.3.
- Heitz-Mayfield, L. J. A., Salvi, G. E., Mombelli, A., Loup, P. J., Heitz, F., Kruger, E. & Lang, N. P. (2018) Supportive peri-implant therapy following anti-infective surgical peri-implantitis treatment: 5-year survival and success. *Clin Oral Implants Res* **29**, 1-6. doi:10.1111/clr.12910.
- Howe, M. S., Keys, W. & Richards, D. (2019) Long-term (10-year) dental implant survival: A systematic review and sensitivity meta-analysis. *J Dent* **84**, 9-21. doi:10.1016/j.jdent.2019.03.008.
- Isler, S. C., Soysal, F., Ceyhanli, T., Bakirarar, B. & Unsal, B. (2018) Regenerative surgical treatment of peri-implantitis using either a collagen membrane or concentrated growth factor: A 12-month randomized clinical trial. *Clin Implant Dent Relat Res* **20**, 703-712. doi:10.1111/cid.12661.
- Karlsson, K., Derks, J., Hakansson, J., Wennstrom, J. L., Petzold, M. & Berglundh, T. (2019) Interventions for peri-implantitis and their effects on further bone loss: A retrospective analysis of a registry-based cohort. *J Clin Periodontol*. doi:10.1111/jcpe.13129.



- Kim, B. S., Kim, Y. K., Yun, P. Y., Yi, Y. J., Lee, H. J., Kim, S. G. & Son, J. S. (2009) Evaluation of peri-implant tissue response according to the presence of keratinized mucosa. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **107**, e24-28. doi:10.1016/j.tripleo.2008.12.010.
- Koldsland, O. C., Wohlfahrt, J. C. & Aass, A. M. (2018) Surgical treatment of peri-implantitis: Prognostic indicators of short-term results. *J Clin Periodontol* **45**, 100-113. doi:10.1111/jcpe.12816.
- Lim, H. C., Wiedemeier, D. B., Hammerle, C. H. F. & Thoma, D. S. (2019) The amount of keratinized mucosa may not influence peri-implant health in compliant patients: A retrospective 5-year analysis. *J Clin Periodontol* **46**, 354-362. doi:10.1111/jcpe.13078.
- Lin, G. H., Chan, H. L. & Wang, H. L. (2013) The significance of keratinized mucosa on implant health: a systematic review. *J Periodontol* **84**, 1755-1767. doi:10.1902/jop.2013.120688.
- Lindhe, J., Meyle, J. & Group, D. o. E. W. o. P. (2008) Peri-implant diseases: Consensus Report of the Sixth European Workshop on Periodontology. *J Clin Periodontol* **35**, 282-285. doi:10.1111/j.1600-051X.2008.01283.x.
- Listgarten, M. A., Lang, N. P., Schroeder, H. E. & Schroeder, A. (1991) Periodontal tissues and their counterparts around endosseous implants [corrected and republished with original paging, article originally printed in *Clin Oral Implants Res* 1991 Jan-Mar;2(1):1-19]. *Clin Oral Implants Res* **2**, 1-19.
- Mombelli, A., Muller, N. & Cionca, N. (2012) The epidemiology of peri-implantitis. *Clin Oral Implants Res* **23 Suppl 6**, 67-76. doi:10.1111/j.1600-0501.2012.02541.x.
- Mombelli, A., van Oosten, M. A., Schurch, E., Jr. & Land, N. P. (1987) The microbiota associated with successful or failing osseointegrated titanium implants. *Oral Microbiol Immunol* **2**, 145-151.
- Monje, A. & Blasi, G. (2019) Significance of keratinized mucosa/gingiva on peri-implant and adjacent periodontal conditions in erratic maintenance compliers. *J Periodontol* **90**, 445-453. doi:10.1002/JPER.18-0471.
- Monje, A., Caballe-Serrano, J., Nart, J., Penarrocha, D., Wang, H. L. & Rakic, M. (2018a) Diagnostic accuracy of clinical parameters to monitor peri-implant conditions: A matched case-control study. *J Periodontol* **89**, 407-417. doi:10.1002/JPER.17-0454.

- Monje, A., Insua, A., Rakic, M., Nart, J., Moyano-Cuevas, J. L. & Wang, H. L. (2018b) Estimation of the diagnostic accuracy of clinical parameters for monitoring peri-implantitis progression: An experimental canine study. *J Periodontol* **89**, 1442-1451. doi:10.1002/JPER.18-0081.
- Monje, A., Wang, H. L. & Nart, J. (2017) Association of Preventive Maintenance Therapy Compliance and Peri-Implant Diseases: A Cross-Sectional Study. *J Periodontol* **88**, 1030-1041. doi:10.1902/jop.2017.170135.
- Perussolo, J., Souza, A. B., Matarazzo, F., Oliveira, R. P. & Araujo, M. G. (2018) Influence of the keratinized mucosa on the stability of peri-implant tissues and brushing discomfort: A 4-year follow-up study. *Clin Oral Implants Res* **29**, 1177-1185. doi:10.1111/clr.13381.
- Pjetursson, B. E., Thoma, D., Jung, R., Zwahlen, M. & Zembic, A. (2012) A systematic review of the survival and complication rates of implant-supported fixed dental prostheses (FDPs) after a mean observation period of at least 5 years. *Clin Oral Implants Res* **23 Suppl 6**, 22-38. doi:10.1111/j.1600-0501.2012.02546.x.
- Renvert, S., Persson, G. R., Pihl, F. Q. & Camargo, P. M. (2018a) Peri-implant health, peri-implant mucositis, and peri-implantitis: Case definitions and diagnostic considerations. *J Clin Periodontol* **45 Suppl 20**, S278-S285. doi:10.1111/jcpe.12956.
- Renvert, S., Roos-Jansaker, A. M. & Persson, G. R. (2018b) Surgical treatment of peri-implantitis lesions with or without the use of a bone substitute—a randomized clinical trial. *J Clin Periodontol* **45**, 1266-1274. doi:10.1111/jcpe.12986.
- Romanos, G., Grizas, E. & Nentwig, G. H. (2015) Association of Keratinized Mucosa and Periimplant Soft Tissue Stability Around Implants With Platform Switching. *Implant Dent* **24**, 422-426. doi:10.1097/ID.0000000000000274.
- Roos-Jansaker, A. M., Lindahl, C., Renvert, H. & Renvert, S. (2006) Nine- to fourteen-year follow-up of implant treatment. Part II: presence of peri-implant lesions. *J Clin Periodontol* **33**, 290-295. doi:10.1111/j.1600-051X.2006.00906.x.
- Roos-Jansaker, A. M., Persson, G. R., Lindahl, C. & Renvert, S. (2014) Surgical treatment of peri-implantitis using a bone substitute with or without a resorbable membrane: a 5-year follow-up. *J Clin Periodontol* **41**, 1108-1114. doi:10.1111/jcpe.12308.

- Sahrman, P., Attin, T. & Schmidlin, P. R. (2011) Regenerative treatment of peri-implantitis using bone substitutes and membrane: a systematic review. *Clin Implant Dent Relat Res* **13**, 46-57. doi:10.1111/j.1708-8208.2009.00183.x.
- Schwarz, F., Becker, J., Civale, S., Sahin, D., Iglhaut, T. & Iglhaut, G. (2018a) Influence of the width of keratinized tissue on the development and resolution of experimental peri-implant mucositis lesions in humans. *Clin Oral Implants Res* **29**, 576-582. doi:10.1111/clr.13155.
- Schwarz, F., Becker, J., Civale, S., Sahin, D., Iglhaut, T. & Iglhaut, G. (2018b) Influence of the width of keratinized tissue on the development and resolution of experimental peri-implant mucositis lesions in humans. *Clin Oral Implants Res*. doi:10.1111/clr.13155.
- Schwarz, F., Derks, J., Monje, A. & Wang, H. L. (2018c) Peri-implantitis. *J Clin Periodontol* **45 Suppl 20**, S246-S266. doi:10.1111/jcpe.12954.
- Schwarz, F., Sahm, N., Schwarz, K. & Becker, J. (2010) Impact of defect configuration on the clinical outcome following surgical regenerative therapy of peri-implantitis. *J Clin Periodontol* **37**, 449-455. doi:10.1111/j.1600-051X.2010.01540.x.
- Serino, G., Turri, A. & Lang, N. P. (2015) Maintenance therapy in patients following the surgical treatment of peri-implantitis: a 5-year follow-up study. *Clin Oral Implants Res* **26**, 950-956. doi:10.1111/clr.12418.
- Silness, J. & Loe, H. (1964) Periodontal Disease in Pregnancy. II. Correlation between Oral Hygiene and Periodontal Condition. *Acta Odontol Scand* **22**, 121-135.
- Sinjab, K., Garaicoa-Pazmino, C. & Wang, H. L. (2018) Decision Making for Management of Periimplant Diseases. *Implant Dent* **27**, 276-281. doi:10.1097/ID.0000000000000775.
- Tonetti, M. S., Greenwell, H. & Kornman, K. S. (2018) Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. *J Periodontol* **89 Suppl 1**, S159-S172. doi:10.1002/JPER.18-0006.
- Ueno, D., Nagano, T., Watanabe, T., Shirakawa, S., Yashima, A. & Gomi, K. (2016) Effect of the Keratinized Mucosa Width on the Health Status of Periimplant and Contralateral Periodontal Tissues: A Cross-sectional Study. *Implant Dent* **25**, 796-801. doi:10.1097/ID.0000000000000483.

Wennstrom, J. L., Bengazi, F. & Lekholm, U. (1994) The influence of the masticatory mucosa on the peri-implant soft tissue condition. *Clin Oral Implants Res* **5**, 1-8.

Wennstrom, J. L. & Derks, J. (2012) Is there a need for keratinized mucosa around implants to maintain health and tissue stability? *Clin Oral Implants Res* **23 Suppl 6**, 136-146.  
doi:10.1111/j.1600-0501.2012.02540.x.

Zigdon, H. & Machtei, E. E. (2008) The dimensions of keratinized mucosa around implants affect clinical and immunological parameters. *Clin Oral Implants Res* **19**, 387-392.  
doi:10.1111/j.1600-0501.2007.01492.x.

Author Manuscript

## Figures and tables legends

**Figure 1.** Implant marginal bone level (MBL) distribution between T0- T1 according to time (years) and keratinized mucosa (KM) width.

**Figure 2.** Changes in probing pocket depths (PPDs) (2A) and implant marginal bone loss (MBL) (2B) between T1- T2 according keratinized mucosa (KM) width.

**Table 1.** Overall demographic data and relevant pre-/post-surgical information at T1

**Table 2.** Clinical and radiographical parameters at T1 prior to the group change of the 13 implants.

**Table 3.** Clinical and radiographical parameters prior to surgical treatment of peri-implantitis (T1).

**Table 4.** Clinical and radiographical parameters between T1 and T2 adjusted by number of maintenance visits and MBL.

**Table 5.** Treatment success rates at final recall (T2)

**Supplementary Table 1.** Description of surgical procedures for the treatment of peri-implantitis

**Supplementary Table 2.** Overall demographic data at T0.

**Supplementary Figure 1.** Flowchart of the study timeline and group allocation according to the KM

**Table 1.** Overall demographic data and relevant prior surgical treatment for peri-implantitis (T1)

	KM		OR	CI 95%	p-value
	≥2mm	<2mm			
<b>n (Implants) T1</b>	29	39			
<b>Mean KM T1 (mm)</b>	3.03 ± 1.59	0.38 ± 0.49			
<b>Time between T1-T2 (months)</b>	60.9 ± 31.3	46.0 ± 28.5	0.98	0.97-1.00	0.075
<b>Implant site (T1)</b>					0.224
Incisor	4 (13.8)	8 (20.5)	1		
Canine	1 (3.4)	4 (10.3)	2.00	0.35-11.3	0.433
Premolar	13 (44.8)	7 (17.9)	0.27	0.06-1.21	0.087
Molar	11 (37.9)	20 (51.3)	0.91	0.21-3.97	0.899
<b>Area (T1)</b>					
Anterior	5 (17.2)	12 (30.8)	1		
Posterior	24 (82.8)	27 (69.2)	0.47	0.11-2.00	0.469
Maxillary	15 (51.7)	11 (28.2)	1		
Mandibular	14 (48.3)	28 (71.8)	2.73	0.91-8.15	0.073
<b>Number of maintenance visits</b>					<b>0.036*</b>
1/per year	16 (55.2)	9 (23.1)	1		
2/per year	8 (27.6)	18 (46.2)	4.00	1.13-14.2	<b>0.032*</b>
≥3/per year	5 (17.2)	12 (30.8)	4.27	1.12-16.3	<b>0.034*</b>
<b>Bone Graft (T1)</b>					
No	14 (51.9)	31 (79.5)	1		
Yes	13 (48.1)	8 (20.5)	0.28	0.09-0.86	<b>0.027*</b>
<b>Implant design (T1)</b>					
Bone level	26 (89.7)	34 (87.2)	1		
Soft tissue level	3 (10.3)	5 (12.8)	1.28	0.28-5.72	0.752
<b>Implant-abutment connection (T1)</b>					0.360
Internal	19 (65.5)	21 (53.8)	1		
External	9 (31.0)	16 (41.0)	1.61	0.46-5.66	0.459
Ball Attachment	1 (3.4)	2 (5.1)	1.81	0.79-4.14	0.160
<b>Type of prosthesis retention (T1)</b>					<b>0.001**</b>
Cement	22 (75.9)	25 (64.1)	1		
Screw	6 (20.7)	10 (25.6)	1.47	0.47-4.60	0.511
Locator/bar attachment	1 (3.4)	4 (10.3)	3.52	1.58-7.83	<b>0.002**</b>
<b>Splinted (T1)</b>					
No	17 (58.6)	13 (33.3)	1		
Yes	12 (41.4)	26 (66.7)	2.83	0.87-9.25	0.084
<b>Opposing dentition (T1)</b>					

Natural	23 (79.3)	29 (74.4)	1		
Others	6 (20.7)	10 (25.6)	1.32	0.32-5.50	0.701
<b>Previous non-surgical therapy</b>					
No	16 (55.2)	16 (41.0)	1		
Yes	13 (44.8)	23 (59.0)	1.77	0.59-5.34	0.312
<b>Surgical approach (T1)</b>					
Regenerative	20 (69.0)	19 (48.7)	1		
Resective	9 (31.0)	20 (51.3)	2.34	0.74-7.41	0.148
<b>Type of bone graft T1(n=39)</b>					
	n=20	n=19			
Allograft	17 (85.0)	18 (94.7)	1		
Xenograft	3 (15.0)	1 (5.3)	0.32	0.05-1.88	0.205
<b>Antibiotics (T1)</b>					
No	9 (31.0)	10 (25.6)	1		0.883
Amoxicillin	13 (44.8)	19 (48.7)	1.32	0.37-4.73	0.675
Azithromycin	2 (6.9)	5 (12.8)	2.25	0.12-43.8	0.593
Clindamycin	5 (17.2)	5 (12.8)	0.90	0.21-3.78	0.886

\*p<0,05; \*\*p<0,01; \*\*\*p<0,001; KM= Keratinized mucosa

**Table 2.** Clinical and radiographical parameters occurring from T0 to T1 utilizing the width KM at T0 as the predictor

	≥2mm	<2mm	OR	CI 95%	p-value
<b>n (Implants)</b>	42	26			
<b>Suppuration</b>					
No	17 (40.5)	4 (15.4)	1		
Yes	25 (59.5)	22 (84.6)	5.02	1.22-20.6	<b>0.025*</b>
<b>BOP</b>					
No	0 (0.0)	0 (0.0)			
Yes	42 (100)	26(100)	--	--	1.000
<b>% MBL</b>					
<25%	30 (73.3)	5 (19.2)	1		<b>0.014*</b>
25-50%	9 (21.5)	13 (50.0)	5.43	1.45-20.4	<b>0.012*</b>
>50%	3 (7.2)	8 (30.8)	10.9	1.75-67.9	<b>0.011*</b>
<b>Mean MBL (mm)</b>	2.66 ± 1.24	4.38 ± 2.13	1.62	1.15-2.28	<b>0.005**</b>
<b>Mean PPD (mm)</b>	5.67 ± 1.59	5.75 ± 1.34	0.88	0.62-1.24	0.451

MBL: Marginal Bone level, BOP: Bleeding on probing PPD: peri-implant probing depths

**Table 3.** Clinical and radiographical parameters prior to surgical treatment of peri-implantitis (T1).

	KM		OR	CI 95%	p-value
	≥2mm	<2mm			
<b>n (Implants)</b>	29	39			
<b>Suppuration</b>					
No	13 (44.8)	8 (20.5)	1		
Yes	16 (55.2)	31 (79.5)	3.15	0.99-10.0	0.052
<b>BOP</b>					



No	0 (0.0)	0 (0.0)			
Yes	29 (100)	39 (100)	--	--	1.000
<b>% MBL</b>					<b>0.004**</b>
<25%	22 (75.9)	13 (33.3)	1		
25-50%	5 (17.2)	17 (43.6)	6.22	1.79-21.7	<b>0.004**</b>
>50%	2 (6.9)	9 (23.1)	8.25	1.45-47.0	<b>0.018*</b>
<b>Mean MBL (mm)</b>	2.47 ± 1.25	3.98 ± 1.95	1.87	1.23-2.85	<b>0.003**</b>
<b>Mean PPD (mm)</b>	5.79 ± 1.57	5.63 ± 1.44	0.93	0.69 -1.26	0.628

\*p<0,05; \*\*p<0,01; \*\*\*p<0,001 MBL: Marginal Bone level, BOP: Bleeding on probing PPD: peri-implant probing depths


**Table 4.** Clinical and radiographical parameters between T1 and T2 adjusted by number of maintenance visits and MBL utilizing KM at T1 as predictor

	Implant failure		OR	CI 95%	p-value
	No	Yes			
<b>n (implant)</b>	56	12			
<b>KM</b>					
≥ 2mm	28 (96.6)	1 (3.4)	1		
< 2mm	28 (71.8)	11 (28.2)	5.55	0.59-52.3	0.13
<b>Number of maintenance visits</b>			0.96	0.45 - 2.05	0.91
<b>MBL</b>			1.65	0.99-2.72	0.05


# Author Manuscript

**Table 5.** Treatment success rate at final recall (T2)

	KM		OR	CI 95%	p-value
	≥2mm	<2mm			
<b>n (Implants)</b>	29	39			
<b>Criteria 1</b>					
Success	3 (10.3)	3 (7.7)	1		
Failure	26 (89.7)	36 (92.3)	1.39	0.26-7.41	0.704
<b>n (Implants)</b>	22	17			
<b>Criteria 2 (Regeneration)</b>					
Success	2 (9.1)	4 (23.5)	1		
Failure	20 (90.9)	13 (76.5)	0.33	0.04-2.65	0.299



jcpe\_13250\_f1.tiff



jcpe\_13250\_f2.tiff